v3.25.4
Credit impairment charges/(releases) (Tables)
12 Months Ended
Dec. 31, 2025
Disclosure of impairment loss and reversal of impairment loss [abstract]  
Disclosure of credit impairment charges and other provisions
2025
2024
2023
Impairment
charges/
(releases)
Recoveries and
reimbursements1
Total2,3
Impairment
charges/
(releases)
Recoveries and
reimbursements1
Total2
Impairment
charges/
(releases)
Recoveries and
reimbursements1
Total
£m
£m
£m
£m
£m
£m
£m
£m
£m
Loans and advances at
amortised cost4
2,452
(180)
2,272
2,115
(94)
2,021
2,017
(73)
1,944
Off-balance sheet loan
commitments and financial
guarantee contracts
1
—
1
(46)
—
(46)
(61)
—
(61)
Total
2,453
(180)
2,273
2,069
(94)
1,975
1,956
(73)
1,883
Cash collateral and settlement
balances
1
—
1
(3)
—
(3)
4
—
4
Financial instruments at fair
value through other
comprehensive income
(3)
—
(3)
1
—
1
(1)
—
(1)
Reverse repurchase agreements
and other similar secured
lending at amortised cost
5
—
5
8
—
8
—
—
—
Other financial assets measured
at amortised cost
3
—
3
1
—
1
(5)
—
(5)
Credit impairment charges /
(releases)
2,459
(180)
2,279
2,076
(94)
1,982
1,954
(73)
1,881
Notes:
1Recoveries and reimbursements include £84m (2024: £15m, 2023: £29m) for reimbursements where the Group has entered into financial guarantee contracts that
provide credit protection over certain assets with third parties and cash recoveries of previously written off amounts of £96m (2024: £79m, 2023: £44m).
2Includes net impairment charge on co-branded card portfolio of £176m (2024:£160m) within USCB classified as held for sale.
3Includes net impairment charge of £101m related to the acquisition of GM  portfolio .
4Includes debt securities at amortised cost.